With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal update from its Phase 3 CAPTIVATE trial. The company, which specializes in "next-generation" complement inhibitors, announced that its lead candidate, claseprubart (DNTH103), met early responder [...]
Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of its late-stage trial.
As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster" that could sustain their independence. Today, Argenx (NASDAQ: ARGX) has effectively ended that search, cementing its status as a global biopharmaceutical powerhouse. Following its full-year 2025 earnings [...]
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a significant 15% stock surge, a move driven by clinical validation of its diversified "Vant" model. This recent rally—pushing shares toward a yearly high of $24.21—is primarily [...]
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine franchise by Pfizer Inc. (NYSE: PFE) in 2022, the "new" Biohaven—often called Biohaven 2.0—is grappling with the harsh realities of clinical-stage drug development. The [...]
As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated 2024 and 2025, characterized by a relentless pursuit of high-end GPUs and massive data center build-outs, has matured into what
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P 500 (INDEXSP: .INX) is finishing the year near the psychological 7,000 mark, a milestone that
ARGENX (ARGX) stock combines strong technical trends with explosive fundamental growth in EPS and sales, making it a high-momentum candidate for investors.
Argenx SE shows strong earnings momentum, soaring revenue growth, and high profitability, aligning with Louis Navellier's systematic growth stock criteria.
